7,376.86

+23.13

+0.31%

51,285.73

-237.33

-0.46%

24,579.42

+264.43

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,074.90

-38.60

-0.94%

75,642.16

-156.98

-0.21%

Crude Oil Dec 26

90.83

+0.31

+0.34%

US Private Equity

10,772.76

+11.83

+0.11%

Frankfurt - Delayed Quote EUR

Fresenius Medical Care AG (FME.F)

42.25 -0.03 (-0.07%)

At close: November 6 at 6:53:33 PM GMT+1

Loading Chart for FME.F

Chart Range Bar

Interval:

In partnership with ChartIQ

Fresenius Medical Care AG (FMS) (Q3 2026) Earnings Call Highlights: Stable Revenue, 5008X ...

Fresenius Medical Care AG (FMS) (Q3 2026) Earnings Call Highlights: Stable Revenue, 5008X ...

What Fresenius Medical Care AG & Co. KGaA (FMS) Said on Its Q3 Earnings Call

What Fresenius Medical Care AG & Co. KGaA (FMS) Said on Its Q3 Earnings Call

Fresenius Medical Care AG & Co. KGaA Q3 2026 Earnings Call Summary

Fresenius Medical Care AG & Co. KGaA Q3 2026 Earnings Call Summary

Fresenius Medical Care (XTRA:FME) Stock May Trade Below Fair Value On Its FDA Cleared AKI System Launch

Fresenius Medical Care (XTRA:FME) Stock May Trade Below Fair Value On Its FDA Cleared AKI System Launch

Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook

Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook

Fresenius: Q3 Earnings Snapshot

Fresenius: Q3 Earnings Snapshot

FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI

FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI

Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth

Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth

Mobilize your Website

View Site in Mobile | Classic

Share by: